GHK-Cu

Summary

GHK-Cu is a naturally occurring tripeptide (glycine-histidine-lysine) that binds a copper ion and is found in human blood plasma, saliva, and urine. First isolated in 1973 by Loren Pickart, it has been studied for decades for its roles in wound healing, collagen synthesis, and skin remodeling. The important distinction most discussions miss: topical GHK-Cu (the cream/serum used in skincare) has real, if modest, human clinical data and is a widely-used legal cosmetic ingredient. Injectable GHK-Cu (the subcutaneous form biohackers use for "systemic anti-aging") has essentially no controlled human evidence and cannot be legally compounded. These are functionally two different products, and the evidence for one does not transfer to the other.

What people use it for

In mainstream skincare, topical GHK-Cu (sold as "Copper Tripeptide-1") is used for anti-aging — wrinkle reduction, skin firming, improved skin density and texture — and for post-procedure recovery (after laser resurfacing, microneedling, chemical peels). In biohacker and peptide communities, injectable GHK-Cu is used for systemic anti-aging, wound healing, hair growth, and general "tissue repair." These are the claims the evidence sections test; describing them is not endorsement.

Human evidence

Topical (where the real data is). Several controlled facial studies have tested topical GHK-Cu creams on human skin. In the most-cited trial, 71 women with mild-to-advanced signs of photoaging applied a GHK-Cu facial cream for 12 weeks; the treatment increased skin density and thickness while reducing laxity, fine lines, and wrinkle depth. A separate trial had 41 women apply a GHK-Cu eye cream for 12 weeks and reported reduced lines and wrinkles and improved skin density, outperforming both placebo and vitamin K cream. Pilot studies by other groups have confirmed increases in skin thickness, hydration, and collagen synthesis with topical copper-peptide complexes. An additional trial found that GHK-Cu cream applied to thigh skin for 12 weeks increased collagen production in 70% of women treated, versus 50% for vitamin C and 40% for retinoic acid.

These are legitimate human studies, but they are small, short, and typically industry-sponsored, with some lacking rigorous blinding. One trial that did use tighter controls — a randomized study of topical GHK-Cu on CO2 laser-resurfaced skin — found no significant difference in erythema resolution between GHK-Cu and control groups, though it was also small (13 patients). A new Phase 2 wound-healing trial (topical GHK-Cu gel for acute skin wounds, NCT07437586) has been registered but is not yet completed. So the topical evidence is promising and consistent for cosmetic skin improvement but not conclusive, and the wound-healing picture is less settled.

Injectable (where the data isn't). For subcutaneous or intramuscular GHK-Cu — the form people actually inject — there are no published controlled human trials testing efficacy for systemic anti-aging, tissue repair, or any other indication. The injectable claims rely entirely on extrapolation from the topical human studies and from animal data (below), which is a different molecule route and dose. That extrapolation is the same bait-and-switch pattern seen in the TB-500 brief: the credible human data is for one product, and the marketing borrows it for another.

Animal / preclinical evidence

The animal and cell-culture evidence for GHK-Cu is among the strongest and most long-standing in this space, spanning over 40 years. In a well-cited 1993 study (Maquart et al., J Clin Invest), GHK-Cu applied to rat wounds stimulated collagen and glycosaminoglycan accumulation. In an ischemic rat-wound model, topical GHK-Cu reduced wound size substantially over 13 days versus controls. Mouse studies have shown GHK-Cu injected at one site improved healing at distant body areas (a systemic effect), increased hair follicle growth near wounds, and stimulated angiogenesis, fibroblast activity, and nerve outgrowth. In-vitro work (Badenhorst et al. 2016) confirmed that GHK-Cu at low concentrations increased collagen and elastin production by human fibroblasts. Gene-expression studies propose that GHK-Cu affects a large number of human genes related to tissue repair, anti-oxidant response, and anti-inflammatory pathways.

The preclinical base is strong enough — from multiple independent groups — that it supports the mechanistic claims with more confidence than many peptides on this site. The caveat is that animal wound-healing and topical skin data does not establish that systemic injection in humans will produce the anti-aging effects being marketed.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

For topical GHK-Cu, user reports in skincare communities are broadly positive and consistent with the trial data — improved skin texture, faster post-procedure recovery, fewer fine lines. For injectable GHK-Cu, users report subjective improvements in skin quality, joint health, and "recovery," typically based on personal experience without controlled comparison. Because injectable GHK-Cu is sourced from gray-market research-chemical vendors, product quality is an additional variable that community reports cannot account for.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

Published human trials used topical GHK-Cu formulations (typically creams or serums at cosmetic concentrations) applied to skin once or twice daily for 12 weeks. The in-vitro fibroblast work tested GHK-Cu at 0.01, 1, and 100 nM concentrations. For injectable use, there are no published human efficacy trials and therefore no validated dose; community protocols (typically 1–2 mg subcutaneously, 2–3 times weekly) are not derived from controlled data.

Safety & side effects

Topical GHK-Cu has been used in cosmetic products for decades with a good safety record; the human trials did not report significant adverse effects, and it is considered well tolerated as a skincare ingredient. The main topical concern is potential skin sensitivity or irritation (patch testing before use is advised). For injectable use, the safety profile is not established by controlled human data; the FDA flags potential immunogenicity (immune reactions) and peptide-impurity concerns for injectable GHK-Cu specifically. Copper toxicity is a theoretical concern at high systemic doses, though Pickart has estimated the toxic threshold as far above any plausible therapeutic dose. Gray-market injectable vials carry the usual unregulated-product risks: contamination, incorrect identification, and inconsistent dosing.

Regulatory / legal status

GHK-Cu exists in three regulatory lanes, and they are not the same:

OTC cosmetic (Copper Tripeptide-1): Fully legal, widely sold, regulated as a cosmetic ingredient. This is the form with the most human data.

Physician-prescribed compounded topical: Legal when prescribed by a licensed physician and prepared by a 503A/503B compounding pharmacy. This is the gold-standard access route for therapeutic-strength topical GHK-Cu.

Injectable: In FDA compounding Category 2 (significant safety concerns). 503A and 503B compounding pharmacies cannot legally compound injectable GHK-Cu in the United States. It is scheduled for review at the February 2027 PCAC meeting. Any injectable GHK-Cu reaching consumers comes through unregulated gray-market channels. GHK-Cu is not FDA-approved as a drug for any indication. Status can change; this is not legal advice.

Podcast / media mentions

GHK-Cu was discussed on the Huberman Lab podcast episode "Peptides: The Science, Uses & Safety" with Dr. Abud Bakri (June 1, 2026), in segments covering its collagen-stimulating mechanism (~1:50:33) and its use as a topical cream alongside red-light therapy (~2:15:36). The distinction between topical and injectable use is the important thing to listen for in any podcast discussion: when a physician discusses GHK-Cu in the context of creams and post-procedure care, that is backed by real human data; when the conversation slides to injectable systemic use, it is extrapolating from a different evidence base. The biology is genuinely interesting, but the legal and evidentiary picture depends entirely on the route.